Article
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated.
Journal of translational medicine - 11 May 2020
Al Hashmi Muna, Sastry Konduru S, Silcock Lee, Chouchane Lotfi, Mattei Valentina, James Nicola, Mathew Rebecca, Bedognetti Davide, De Giorgi Valeria, Murtas Daniela, Liu Wei, Chouchane Aouatef, Temanni Ramzi, Seliger Barbara, Wang Ena, Marincola Francesco M, Tomei Sara
Abstract excerpt
BACKGROUND: Most mutations in melanoma affect one critical amino acid on BRAF gene, resulting in the V600E substitution. Patient management is often based on the use of specific inhibitors targeting this mutation. METHODS: DNA and RNA mutation status was assessed in 15 melanoma cell lines by Sanger sequencing and RNA-seq. We tested the cell lines responsiveness to BRAF inhibitors (vemurafenib and PLX4720,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.